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I read with great interest the recent article by Luk et al. in
a recent issue of your esteemed journal [1]. The article is
highly thought provoking. Interestingly, the past few years
have clearly revealed the connection between morphine
administration and tumor development and progression.
For instance, morphine acts on the µ-opioid receptors
and increases intracellular cyclin D1 and activates G protein
receptors resulting in accentuation of the mitogen-activated
protein kinase (MAPK) pathway and thereby enhances
angiogenesis in breast tumor cells [2]. In fact Farooqui et
al.haverecentlydemonstratedthatmorphineadministration
in breast tumor animal models activates prostaglandin E2
thereby enhancing tumor metastasis also. Similar eﬀects are
notedinprostatecancertissue[3].Forinstance,patientswho
undergo radical prostatectomy for prostate carcinoma and
who receive opioid treatment in conjunction with general
anesthesia have a 57% higher risk of tumor recurrence in
comparison to patients who receive general anesthesia in
conjunction with epidural anesthesia [4]. Similarly, Mathew
et al. have shown that morphine administration enhances
t u m o rg r o w t hi nl u n gc a n c e rm o d e l s[ 5].
Interestingly, methylnaltrexone inhibits activation of
RhoA by inhibiting transactivation of VEGF receptors [6].
As a result it attenuates morphine-induced angiogenesis
and thus inhibits tumor growth. PD98059 is another new
agent that inhibits the MAPK pathway and thereby dec-
reases opioid-induced tumor cell proliferation [7]. Sim-
ilarly, celecoxib attenuates opioid-induced stimulation of
cyclooxygenase-2 receptors and thereby exerts antineoplastic
eﬀects [3].
These examples clearly illustrate the role of morphine in
enhancing tumor angiogenesis and growth. Clearly, there is
a further need to identify further such opioid receptor antag-
onists besides methylnaltrexone that can inhibit morphine-
mediated carcinogenesis.
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